重大事件
即時報告
8-K
2026-07-20
Seer 特別委員會拒絕 CEO 每股2.45美元現金加CVR收購要約
AI 繁中摘要
📄 **美國 SEC 8-K 申報摘要 – Seer, Inc. (Nasdaq: SEER)**
**日期：2026年7月20日**
Seer 董事會轄下特別委員會（由獨立董事 Meeta Gulyani 及 Nicolas Roelofs 組成）一致拒絕由公司主席兼 CEO Omid Farokhzad 提出的非約束性收購建議。該建議於2026年7月1日提交，計劃以每股 **2.45 美元現金** 加上兩項或有價值權（CVR）收購 Seer 所有已發行 A 類普通股。
特別委員會在獨立顧問協助下詳細審議，一致認為該要約 **低估 Seer 的長期增長潛力**，不符合股東最佳利益。委員會指出，要約中的 CVR 雖然旨在讓股東從公司技術未來發展中獲益，但條款不足以充分反映 Seer 的真實價值及增長前景。
💼 **潛在影響**：此次拒絕顯示董事會對公司獨立發展的信心，短期內或支撐股價避免低價收購，但可能引發市場對後續股東行動或進一步報價的關注。投資者需留意公司後續披露及任何修訂要約。
🔍 **背景**：Seer 為蛋白質組學領域先驅，其 Proteograph® 產品平台利用專利納米粒子技術，提供深度、無偏見的蛋白質分析。公司產品僅限研究用途，不用於診斷。
展開英文正文
EX-99.1 2 d105079dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D. REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the “Proposal”). Consistent with its fiduciary duties, the Special Committee carefully reviewed the Proposal in consultation with its independent advisors and unanimously determined that it is not in the best interests of Seer’s stockholders because it undervalues Seer and fails to reflect the value of Seer’s long-term growth prospects. In reaching this conclusion, the Special Committee noted that the contingent value rights included in the Proposal, which are intended to allow Seer’s stockholders to benefit from future developments related to Seer’s technology, were insufficient to fully value Seer and its growth potential. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph ® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio. For more information, please email us at [email protected]. Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s prospects, growth potential and technology. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Media Contact: Patrick Schmidt [email protected] Joele Frank, Wilkinson Brimmer Katcher Eric Brielmann / Joseph Sala (212) 355-4449 Investor Contact: Marissa Bych [email protected]